Search research articles
Contact Us
Filters
Showing results (121-130 of 138) with videos related to
Page
of 14
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 10, 2016
Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer
E Vrdoljak, N Marschner, C Zielinski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 1, 1996
Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group
R C Coombes, J M Bliss, J Wils, et al.
Breast Cancer Research and Treatment
|
November 30, 2004
HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel
A Di Leo, S Chan, M Paesmans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 2, 2007
Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel
M Aapro, P A Abrahamsson, J J Body, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 25, 2016
2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients
F Roila, A Molassiotis, J Herrstedt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2025
Personalised antiemetic prophylaxis with NEPA for patients at high risk of chemotherapy-induced nausea and vomiting receiving moderately emetogenic chemotherapy: results from the randomised, multinational MyRisk trial
A Molassiotis, K Jordan, M Karthaus, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 18, 2010
Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference
F Roila, J Herrstedt, M Aapro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 19, 2015
Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel
P Hadji, R E Coleman, C Wilson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 20, 1999
Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group
J M Nabholtz, H J Senn, W R Bezwoda, et al.
Breast (Edinburgh, Scotland)
|
March 20, 2012
1st International consensus guidelines for advanced breast cancer (ABC 1)
F Cardoso, A Costa, L Norton, et al.
Page
of 14
Search research articles
Search
Showing results (121-130 of 138) with videos related to
Sort By:
Page
of 14
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 10, 2016
Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer
E Vrdoljak, N Marschner, C Zielinski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 1, 1996
Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group
R C Coombes, J M Bliss, J Wils, et al.
Breast Cancer Research and Treatment
|
November 30, 2004
HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel
A Di Leo, S Chan, M Paesmans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 2, 2007
Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel
M Aapro, P A Abrahamsson, J J Body, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 25, 2016
2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients
F Roila, A Molassiotis, J Herrstedt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2025
Personalised antiemetic prophylaxis with NEPA for patients at high risk of chemotherapy-induced nausea and vomiting receiving moderately emetogenic chemotherapy: results from the randomised, multinational MyRisk trial
A Molassiotis, K Jordan, M Karthaus, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 18, 2010
Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference
F Roila, J Herrstedt, M Aapro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 19, 2015
Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel
P Hadji, R E Coleman, C Wilson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 20, 1999
Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group
J M Nabholtz, H J Senn, W R Bezwoda, et al.
Breast (Edinburgh, Scotland)
|
March 20, 2012
1st International consensus guidelines for advanced breast cancer (ABC 1)
F Cardoso, A Costa, L Norton, et al.
Page
of 14